Specialty generic pharmaceutical firm launches primary care division in Philippines

Upgrade to High-Speed Internet for only ₱1499/month!

Enjoy up to 100 Mbps fiber broadband, perfect for browsing, streaming, and gaming.

Visit Suniway.ph to learn

April 24, 2026 | 11:59am

MANILA, Philippines — Sun Pharmaceutical Industries officially launched its Primary Care Division in the Philippines with the unveiling of the CaRMeLin Portfolio — a comprehensive therapeutic line dedicated to cardiometabolic, renal, liver and alimentary care.

The scientific launch event gathered many of the country’s top key opinion leaders in internal medicine, cardiology, endocrinology, nephrology and primary care, making it one of the most distinguished medical assemblies of the year. This milestone marks the company’s formal and strategic entry into the largest therapeutic segment in Philippine healthcare.

A keynote lecture from Dr. Raymond Townsend, professor of Medicine at the University of Pennsylvania and a global authority in hypertension and chronic kidney disease, anchored the program.

Serving as the scientific chair, Dr. Gerry H. Tan, a Mayo Clinic-trained endocrinologist and one of Asia’s leading voices in diabetes and metabolic medicine, underscored the significance of this launch.

“As the world’s fourth-largest specialty generic company, Sun Pharma’s launch in the Philippines sets a new benchmark in manufacturing excellence and strengthens the country’s supply security for affordable specialty generics. In critical fields like mine — diabetes and endocrinology — where precision and bioequivalence are non-negotiable, this is a true game-changer for Filipino patients,” Tan said. 

The CaRMeLin Portfolio introduces high-quality, internationally benchmarked generics that address significant gaps in clinical access — particularly in hypertension, diabetes, liver disease and alimentary disorders. The portfolio also features bioequivalent and therapeutically equivalent molecules poised for first-generic status in their respective categories.

Generics have long delivered comparable efficacy and safety to innovator medicines, and with Sun Pharma’s unwavering commitment to global manufacturing excellence, Filipino physicians and patients can rely on affordable, consistent and accessible treatment options.

According to Sharon Pablo, country head of Sun Pharma Philippines and the first Filipina to lead the organization: “It is our commitment to Filipino patients to provide affordable, reliable, and high-quality branded generics — medicines built on global standards and proven scientific rigor. Through our mission of Reaching People, Touching Lives, we aim to expand access, empower care and make meaningful health outcomes possible for every Filipino we serve.”

RELATED: 'Stop Rabies' initiative seeks to achieve rabies-free Philippines